Rafferty Asset Management LLC Raises Position in Moderna, Inc. (NASDAQ:MRNA)

Rafferty Asset Management LLC increased its holdings in Moderna, Inc. (NASDAQ:MRNAGet Rating) by 3.1% during the second quarter, Holdings Channel.com reports. The firm owned 91,036 shares of the company’s stock after acquiring an additional 2,780 shares during the quarter. Rafferty Asset Management LLC’s holdings in Moderna were worth $13,004,000 at the end of the most recent quarter.

A number of other large investors also recently added to or reduced their stakes in MRNA. RB Capital Management LLC raised its position in Moderna by 7.5% in the 1st quarter. RB Capital Management LLC now owns 2,267 shares of the company’s stock worth $391,000 after purchasing an additional 158 shares during the period. DAVENPORT & Co LLC grew its holdings in Moderna by 89.5% in the 1st quarter. DAVENPORT & Co LLC now owns 1,808 shares of the company’s stock worth $311,000 after acquiring an additional 854 shares during the last quarter. Venture Visionary Partners LLC grew its holdings in Moderna by 7.3% in the 1st quarter. Venture Visionary Partners LLC now owns 1,841 shares of the company’s stock worth $317,000 after acquiring an additional 125 shares during the last quarter. Ausdal Financial Partners Inc. grew its holdings in Moderna by 13.4% in the 1st quarter. Ausdal Financial Partners Inc. now owns 1,202 shares of the company’s stock worth $207,000 after acquiring an additional 142 shares during the last quarter. Finally, Envestnet Asset Management Inc. grew its holdings in Moderna by 32.0% in the 1st quarter. Envestnet Asset Management Inc. now owns 83,023 shares of the company’s stock worth $14,302,000 after acquiring an additional 20,121 shares during the last quarter. Hedge funds and other institutional investors own 60.76% of the company’s stock.

Moderna Trading Down 1.5 %

Shares of MRNA traded down $2.78 during trading hours on Thursday, reaching $176.81. 2,311,841 shares of the company traded hands, compared to its average volume of 4,704,397. Moderna, Inc. has a 12 month low of $115.03 and a 12 month high of $376.65. The company has a quick ratio of 1.80, a current ratio of 2.10 and a debt-to-equity ratio of 0.05. The company’s fifty day moving average price is $143.11 and its two-hundred day moving average price is $146.64. The company has a market capitalization of $67.93 billion, a price-to-earnings ratio of 6.40, a price-to-earnings-growth ratio of 1.28 and a beta of 1.74.

Wall Street Analysts Forecast Growth

MRNA has been the topic of a number of recent analyst reports. SVB Leerink raised shares of Moderna from an “underperform” rating to a “market perform” rating and cut their price target for the stock from $174.00 to $101.00 in a report on Friday, October 21st. Morgan Stanley cut their price target on shares of Moderna from $175.00 to $170.00 and set an “equal weight” rating on the stock in a report on Friday, November 4th. Deutsche Bank Aktiengesellschaft raised shares of Moderna from a “hold” rating to a “buy” rating and raised their price target for the stock from $155.00 to $165.00 in a report on Wednesday, September 7th. JPMorgan Chase & Co. cut their price target on shares of Moderna from $165.00 to $122.00 and set a “neutral” rating on the stock in a report on Monday, October 24th. Finally, Cowen cut their target price on shares of Moderna from $165.00 to $145.00 in a research note on Thursday, October 20th. Seven research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $176.93.

Insider Buying and Selling

In related news, CEO Stephane Bancel sold 40,000 shares of the business’s stock in a transaction dated Wednesday, September 7th. The shares were sold at an average price of $133.68, for a total transaction of $5,347,200.00. Following the sale, the chief executive officer now owns 5,411,946 shares of the company’s stock, valued at $723,468,941.28. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, Director Noubar Afeyan sold 10,000 shares of the business’s stock in a transaction dated Wednesday, October 5th. The shares were sold at an average price of $122.40, for a total transaction of $1,224,000.00. Following the sale, the director now owns 2,387,209 shares of the company’s stock, valued at $292,194,381.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Stephane Bancel sold 40,000 shares of the business’s stock in a transaction dated Wednesday, September 7th. The stock was sold at an average price of $133.68, for a total transaction of $5,347,200.00. Following the sale, the chief executive officer now directly owns 5,411,946 shares in the company, valued at approximately $723,468,941.28. The disclosure for this sale can be found here. Insiders have sold 483,436 shares of company stock valued at $64,832,812 over the last quarter. Corporate insiders own 17.30% of the company’s stock.

Moderna Profile

(Get Rating)

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines.

Recommended Stories

Want to see what other hedge funds are holding MRNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Moderna, Inc. (NASDAQ:MRNAGet Rating).

Institutional Ownership by Quarter for Moderna (NASDAQ:MRNA)

Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.